Voting Rights and Shares Capital of the Company

Rhea-AI Summary

Nanobiotix (Nasdaq: NBTX) disclosed its voting rights and share capital as of February 28, 2026. The company reported 48,494,528 shares outstanding, 50,197,214 theoretical voting rights, and 50,175,096 exercisable voting rights.

Listing: Euronext Paris and Nasdaq; document explains calculation of gross and net voting rights under AMF rules.

News Market Reaction – NBTX

+4.92%

4 alerts

+4.92% News Effect

+11.9% Peak Tracked

+$72M Valuation Impact

$1.54B Market Cap

0.1x Rel. Volume

On the day this news was published, NBTX gained 4.92%, reflecting a moderate positive market reaction. Argus tracked a peak move of +11.9% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $72M to the company's valuation, bringing the market cap to $1.54B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Shares outstanding: 48,494,528 Theoretical voting rights: 50,197,214 Exercisable voting rights: 50,175,096 +5 more

8 metrics

Shares outstanding 48,494,528 As of February 28, 2026

Theoretical voting rights 50,197,214 As of February 28, 2026

Exercisable voting rights 50,175,096 As of February 28, 2026

Patent families More than 25 Nanobiotix IP portfolio

Nanotechnology platforms 3 Oncology, bioavailability/biodistribution, CNS disorders

Incorporation year 2003 Company founding year

52-week high 41.8899 Pre-news 52-week high price

52-week low 2.95 Pre-news 52-week low price

Market Reality Check

Price: $34.00 Vol: Volume 92,046 is 1.78x th...

high vol

$34.00 Last Close

Volume Volume 92,046 is 1.78x the 20-day average of 51,766 shares ahead of this disclosure. high

Technical Price at 33.24 is trading above the 200-day MA of 16.11, despite a -14% move over 24h and sitting 20.65% below the 41.8899 52-week high after a large gain from the 2.95 52-week low.

Peers on Argus

NBTX was down 14% with elevated volume, while key biotech peers showed only mode...

1 Down

NBTX was down 14% with elevated volume, while key biotech peers showed only modest moves (e.g., REPL -3.42%, ARCT -2.1%, BCYC -1.13%, OPT -2.01%, ERAS +0.65%). This points to stock-specific dynamics rather than a broad sector move.

Common Catalyst One peer, ERAS, reported earnings, but broader peer news flow was limited, suggesting today’s NBTX move is not part of a shared news theme.

Historical Context

5 past events · Latest: Feb 25 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Investor conferences	Neutral	+1.4%	Participation in multiple March investor conferences to present the company.
Feb 17	Voting rights update	Neutral	+1.1%	Disclosure of Jan 31, 2026 share count and voting-rights details.
Jan 13	Voting rights update	Neutral	+0.7%	Report of Dec 31, 2025 shares outstanding and voting-rights figures.
Dec 17	Voting rights update	Neutral	+3.1%	Disclosure of Nov 30, 2025 voting rights and share capital per French rules.
Dec 15	Index inclusion	Positive	-1.6%	Admission to CAC Mid 60 and SBF 120 indices on Euronext Paris.

Pattern Detected

Routine French voting-rights disclosures have historically coincided with small positive moves, while a clearly positive index-inclusion event previously saw a modest negative reaction.

Recent Company History

Over the past few months, Nanobiotix has mainly issued administrative and capital-structure disclosures alongside visibility-building initiatives. Multiple “Voting Rights and Shares Capital” releases in Dec 2025, Jan 2026, and Feb 2026 reported incremental changes in outstanding shares and voting rights, with modest positive price reactions. A Dec 15, 2025 index-inclusion announcement into the CAC Mid 60 and SBF 120 saw a slight negative move, showing that even clearly positive developments have not always translated into immediate price strength.

Market Pulse Summary

This announcement formalizes Nanobiotix’s share count and voting-rights structure as of February 28,...

Analysis

This announcement formalizes Nanobiotix’s share count and voting-rights structure as of February 28, 2026, continuing a regular pattern of French law–driven disclosures. It reports 48,494,528 shares outstanding and detailed theoretical versus exercisable voting-rights figures. In context of prior monthly updates, investors may watch how these numbers trend over time alongside regulatory filings and conference participation, as well as how the company’s three nanotechnology platforms and more than 25 patent families support longer-term strategic developments.

Key Terms

isin, voting rights, nanotechnology, oncology, +2 more

6 terms

isin financial

"ISIN code: FR0011341205Nasdaq: NBTX"

A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.

voting rights regulatory

"Total number of voting rights"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

nanotechnology technical

"three (3) nanotechnology platforms with applications in 1) oncology"

Nanotechnology is the design and control of materials and devices at the scale of atoms and molecules — about one-billionth of a meter — allowing scientists to create properties and functions not possible at larger sizes. For investors, it matters because these tiny changes can lead to big improvements in drugs, electronics, materials and manufacturing efficiency, opening new markets and competitive advantages while also bringing technical, cost and regulatory risks.

oncology medical

"applications in 1) oncology; 2) bioavailability and biodistribution"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

biodistribution medical

"2) bioavailability and biodistribution; and 3) disorders of the central nervous system"

Biodistribution is the map of where a drug, vaccine, or diagnostic agent travels and accumulates inside the body after administration. Investors care because where a product ends up affects how well it works, what side effects it may cause, and whether regulators will approve it—similar to tracking dye in a plumbing system to find leaks or blockages; unexpected destinations can raise safety, cost, and market-adoption risks.

central nervous system medical

"3) disorders of the central nervous system."

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

AI-generated analysis. Not financial advice.

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, March 12, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical1	Total voting rights, exercisable2
February 28, 2026	48,494,528	50,197,214	50,175,096

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

________________________________

¹ The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

² The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

Attachment

• 2026-03-12 -- NBTX -- Voting Rights & Shares Capital -- FINAL

FAQ

How many shares outstanding did Nanobiotix (NBTX) report on February 28, 2026?

Nanobiotix reported 48,494,528 shares outstanding as of February 28, 2026. According to the company, this figure is the basis for calculating theoretical voting rights under applicable AMF rules and reflects total issued shares at that date.

What were the total theoretical and exercisable voting rights for NBTX on February 28, 2026?

The company reported 50,197,214 theoretical and 50,175,096 exercisable voting rights on February 28, 2026. According to the company, theoretical rights include suspended votes while exercisable rights exclude treasury-held shares.

Why does Nanobiotix (NBTX) report both theoretical and exercisable voting rights?

Reporting both clarifies voting thresholds and shareholder influence ahead of meetings. According to the company, theoretical voting rights include all attached votes, while exercisable rights exclude shares with suspended voting power, like treasury stock.

Where is Nanobiotix (NBTX) listed and which ISIN applies to the reported shares?

Nanobiotix is listed on Euronext Paris and Nasdaq, using ISIN FR0011341205. According to the company, the ISIN and listings identify the issued share class used for the voting rights disclosure.

How should investors use the NBTX voting rights disclosure dated March 12, 2026?

Investors should use the disclosure to assess voting thresholds and shareholder structure as of February 28, 2026. According to the company, the figures inform threshold crossing calculations and governance-related decisions ahead of shareholder meetings.